Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hipgnosis Songs Fund seeking indemnity from founder

(Sharecast News) - Hipgnosis Songs Fund said in an update on Monday that it was looking for indemnity from its founder amid a legal battle with Hipgnosis Music. The music royalty investor said the lawsuit involved claims from Hipgnosis Music, a company Merck Mercuriadis was a director of, alleging an unlawful diversion of business opportunities to Hipgnosis Songs Fund and its investment advisor, Hipgnosis Songs Management.

It was looking to recover a substantial but unspecified sum, with Hipgnosis Music securing litigation funding.

The company had disclosed the lawsuit in November, and said it had appointed Kastle Solicitors independently to review the allegations.

It said it was seeking indemnity from Mercuriadis and Hipgnosis Songs Management, as any liability would be attributed to their conduct and knowledge.

The news came days after Merck Mercuriadis stepped down as chief executive officer of Hipgnosis Songs Management.

Ben Katovsky, the manager's current chief operating officer, would take over the role, while Mercuriadis would assume the position of chairman and lead the company's engagement with songwriters and artists.

At 0801 GMT, shares in Hipgnosis Songs Fund were down 1.07% at 64.6p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.